X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XFOR X4 Pharmaceuticals Inc

Trading 04-16 15:08:56 EDT

4.10

-0.23

-5.31%

High4.35	Low4.09	Vol192.74K
Open4.30	D1 Closing4.33	Amplitude6.21%
Mkt Cap372.77M	Tradable Cap264.88M	Total Shares90.92M
T/O800.42K	T/O Rate0.30%	Tradable Shares64.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XFOR","market":"US","secType":"STK","nameCN":"X4 Pharmaceuticals Inc","latestPrice":4.1,"timestamp":1776366531808,"preClose":4.33,"halted":0,"volume":192740,"delay":0,"changeRate":-0.053117782909930814,"floatShares":64606000,"shares":90919696,"eps":-1.872634,"marketStatus":"Trading","change":-0.23,"latestTime":"04-16 15:08:56 EDT","open":4.3,"high":4.3537,"low":4.085,"amount":800422.1785779999,"amplitude":0.062055,"askPrice":4.11,"askSize":218,"bidPrice":4.1,"bidSize":415,"shortable":3,"etf":0,"ttmEps":-1.872634,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776369600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1510808400000,"exchange":"NASDAQ","adjPreClose":4.33,"preHourTrading":{"tag":"盘前","latestPrice":4.3499,"preClose":4.33,"latestTime":"08:12 EDT","volume":162,"amount":704.934252,"timestamp":1776341569009,"change":0.0199,"changeRate":0.004596,"amplitude":0.01157},"postHourTrading":{"tag":"盘后","latestPrice":4.33,"preClose":4.33,"latestTime":"19:55 EDT","volume":303,"amount":1314.13,"timestamp":1776297311388,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.716821,"impliedVol":0.72,"impliedVolPercentile":0.8571},"requestUrl":"/m/hq/s/XFOR","defaultTab":"news","newsList":[{"id":"2624492544","title":"BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624492544","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624492544?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:18","pubTimestamp":1775078295,"startTime":"0","endTime":"0","summary":"BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 1 (Reuters) - X4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ L","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUAHQQS4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624502541","title":"X4 Pharmaceuticals issues inducement stock options for 32,000 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2624502541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624502541?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:32","pubTimestamp":1775075536,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals issued inducement stock options covering 32,000 shares, effective March 31, 2026.Options carry a 10-year term with an exercise price of $4.13 per share.Vesting schedule sets 25% after 12 months with remaining balance vesting monthly over next 36 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4Skjl7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","XFOR","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014039.USD","BK4112","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620369287","title":"X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2620369287","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620369287?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:46","pubTimestamp":1774010774,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals will hold its annual meeting virtually on May 11, 2026.Shareholders will vote to elect three Class III director nominees to serve until the 2029 annual meeting.Items up for approval include a 1.5 million-share increase under the Second Amended and Restated 2017 Equity Incentive Plan.A non-binding advisory vote on named executive officer compensation is also scheduled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL2SVM55:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620258086","title":"Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258086?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:40","pubTimestamp":1773834015,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report), Boston ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-x4-pharmaceuticals-xfor-boston-scientific-bsx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-x4-pharmaceuticals-xfor-boston-scientific-bsx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU1291159041.SGD","LU1366192091.USD","LU2087625088.SGD","XLV","LU1989764664.SGD","XFOR","LU0950375773.USD","LU1720051017.SGD","IE00BJJMRZ35.SGD","LU0823417653.USD","LU2265009873.SGD","LU0823416689.USD","LU1061106388.HKD","LU0128526141.USD","LU0238689110.USD","LU1023059063.AUD","LU2491049909.HKD","BK4581","BK4504","LU1718418525.SGD","IE0002141913.USD","SG9999001176.USD","BK4139","LU0345769128.USD","HCSG","LU0266013472.USD","LU2362541273.HKD","SGXZ57979304.SGD","LU0187121727.USD","LU0353189763.USD","LU1720051108.HKD","LU2506952170.USD","LU0267386448.USD","LU2506952097.USD","LU1057294990.SGD","LU0345769631.USD","LU0823417737.USD","LU0048584097.USD","LU1791710400.SGD","BSX","LU1153585028.USD","XBI","IE0009355771.USD","LU0882574055.USD","BK4585","LU1791710582.SGD","LU1989764748.USD","LU2491050154.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426032","title":"X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426032?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUAVCPTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429894","title":"Rpt-X4 Pharmaceuticals Q4 EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429894?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX6E47AA:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429889","title":"X4 Pharmaceuticals Inc - Cash Runway Expected Through 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429889?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX6E47AA:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620142989","title":"X4 Pharmaceuticals Inc - Global 4Ward Phase 3 Chronic Neutropenia Trial on Track to Complete Enrollment in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620142989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620142989?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:15","pubTimestamp":1773746100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLX6E47AA:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426926","title":"X4 Pharmaceuticals FY 2025 net loss widens 111.2% to USD 79.2 million as revenue rises 1,250% to USD 35.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426926","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426926?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:02","pubTimestamp":1773745363,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals published its annual report on Form 10-K for FY 2025, reporting revenue of USD 35.1 million. FY 2025 net loss was USD 79.2 million, while loss from operations was USD 86.9 million. FY 2025 research and development expense fell 10.9% to USD 72.7 million, primarily due to lower spending following 2025 strategic restructurings, partially offset by higher clinical costs for the Phase 3 4WARD trial. FY 2025 general and administrative expense decreased 29.4% to USD 43.5 million, driven by lower headcount and reduced sales and marketing spending versus the prior year’s XOLREMDI launch costs. Management said cash, cash equivalents and restricted cash totaled USD 217.9 million at year-end, and expects cash, cash equivalents and marketable securities to fund operations for at least the next 12 months, while noting full enrollment in the 4WARD trial is expected in Q3 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9sTDw2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618257629","title":"X4 Pharmaceuticals Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2618257629","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618257629?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:16","pubTimestamp":1773062160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XFOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 09:16 ET (13:16 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618640412","title":"X4 Pharmaceuticals initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640412?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:51","pubTimestamp":1773053510,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of X4 Pharmaceuticals (XFOR) with a Buy rating and $12 price target The firm sees the “differentiated hematology play...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/x4-pharmaceuticals-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/x4-pharmaceuticals-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614685835","title":"X4 Pharmaceuticals Receives Positive Opinion From the Ema Chmp Recommending Approval of Mavorixafor in the EU for Whim Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2614685835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614685835?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:02","pubTimestamp":1772193722,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN189:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614583618","title":"X4 Pharmaceuticals: Positive Opinion Will NOW Be Reviewed by European Commission (Ec) With a Final Approval Decision Anticipated in Q2 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614583618","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614583618?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:02","pubTimestamp":1772193722,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN189:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614588538","title":"EMA CHMP recommends EU approval of X4 Pharmaceuticals’ mavorixafor for WHIM syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2614588538","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614588538?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:00","pubTimestamp":1772193656,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals said the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization under exceptional circumstances for mavorixafor to treat WHIM syndrome in the European Union. The opinion will be reviewed by the European Commission, with a final decision expected in the second quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL3W3bKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4112","BK4588","BK4139","XFOR","NDAQ","SG9999014013.SGD","IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","BK4585","SG9999014005.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608873155","title":"X4 Pharmaceuticals to Join Guggenheim Emerging Outlook Biotech Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2608873155","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608873155?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:00","pubTimestamp":1770120014,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit, taking place on February 11-12, 2026, in New York. The company's management team is scheduled to hold a fireside chat on February 12 at 12:30 p.m. ET, with a webcast available on the X4 Pharmaceuticals website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL6Mchc8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","XFOR","SG9999014021.USD","NDAQ","BK4139","SG9999014013.SGD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608789081","title":"BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2608789081","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608789081?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:03","pubTimestamp":1770066202,"startTime":"0","endTime":"0","summary":"BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule Feb 2 (Reuters) - X4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUAC5135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608970168","title":"X4 Pharmaceuticals Grants Stock Options to New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2608970168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608970168?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:01","pubTimestamp":1770066071,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals Inc. has granted inducement stock options to new employees under its 2019 Inducement Equity Incentive Plan. The awards total options to purchase 20,000 shares of common stock at an exercise price of $3.70 per share, matching the closing price on January 30, 2026. Each option has a ten-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL3Csxg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4112","BK4588","BK4139","XFOR","NDAQ","SG9999014013.SGD","IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","BK4585","SG9999014005.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608897064","title":"X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608897064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608897064?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:01","pubTimestamp":1770066060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUAC5135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593472213","title":"X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2593472213","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593472213?lang=en_us&edition=fundamental","pubTime":"2025-12-24 18:22","pubTimestamp":1766571731,"startTime":"0","endTime":"0","summary":"With a median price-to-sales (or \"P/S\") ratio of close to 12.4x in the Biotechs industry in the United States, you...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xfor/x4-pharmaceuticals/news/x4-pharmaceuticals-incs-nasdaqxfor-shares-may-have-run-too-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xfor/x4-pharmaceuticals/news/x4-pharmaceuticals-incs-nasdaqxfor-shares-may-have-run-too-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XFOR","NVIW.SI","QID","TQQQ","NQmain","USJW.SI","MNQmain","PSQ","QLD","TSYW.SI","BK4139","USAW.SI",".IXIC","SQQQ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2582875432","title":"X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875432","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875432?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:18","pubTimestamp":1762777080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XFOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 07:18 ET (12:18 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.x4pharma.com","stockEarnings":[{"period":"1week","weight":0.0691},{"period":"1month","weight":0.2163},{"period":"3month","weight":0.1961},{"period":"6month","weight":0.4579},{"period":"1year","weight":-0.3061},{"period":"ytd","weight":0.0825}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.010739},{"month":2,"riseRate":0.555556,"avgChangeRate":0.007538},{"month":3,"riseRate":0.555556,"avgChangeRate":0.084933},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.017801},{"month":5,"riseRate":0.25,"avgChangeRate":-0.040791},{"month":6,"riseRate":0.125,"avgChangeRate":-0.268932},{"month":7,"riseRate":0.25,"avgChangeRate":-0.039863},{"month":8,"riseRate":0.375,"avgChangeRate":0.07504},{"month":9,"riseRate":0.25,"avgChangeRate":-0.001382},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084011},{"month":11,"riseRate":0.25,"avgChangeRate":0.161316},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.049964}],"exchange":"NASDAQ","name":"X4 Pharmaceuticals Inc","nameEN":"X4 Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest X4 Pharmaceuticals Inc(XFOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"X4 Pharmaceuticals Inc,XFOR,X4 Pharmaceuticals Inc股票,X4 Pharmaceuticals Inc股票老虎,X4 Pharmaceuticals Inc股票老虎国际,X4 Pharmaceuticals Inc行情,X4 Pharmaceuticals Inc股票行情,X4 Pharmaceuticals Inc股价,X4 Pharmaceuticals Inc股市,X4 Pharmaceuticals Inc股票价格,X4 Pharmaceuticals Inc股票交易,X4 Pharmaceuticals Inc股票购买,X4 Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest X4 Pharmaceuticals Inc(XFOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}